Stability of sulfadiazine sugar-free oral suspensions for the treatment of congenital toxoplasmosis
Braz. J. Pharm. Sci. (Online); 59 (), 2023
Abstract This study aimed to develop and evaluate the stability of sulfadiazine sugar-free extemporaneous oral suspensions, focusing on treating congenital toxoplasmosis. The excipients were carefully chosen to obtain safe products for the pediatric population. Sulfadiazine suspensions (100 mg/ mL) were ...